<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281472</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-1802</org_study_id>
    <secondary_id>2019-003076-39</secondary_id>
    <nct_id>NCT04281472</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)</brief_title>
  <acronym>ADHERE</acronym>
  <official_title>A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx BVBA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx BVBA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation
      of efgartigimod in adults with CIDP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage A: Percentage of patients with confirmed evidence of clinical improvement(ECI)</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage B: Time to first adjusted INCAT deterioration compared to Stage B baseline</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage A: Time to initial confirmed ECI</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in adjusted INCAT score</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in Medical Research Council (MRC) Sum score</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in I-RODS disability scores</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in TUG score</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in mean grip strength</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Exposure adjusted occurrence of treatment-emergent (serious) adverse events</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Incidence of clinically significant laboratory abnormalities</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Pre-dosing efgartigimod serum concentrations over time</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Changes of serum IgG levels over time</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Percentage of patients with and titers of binding antibodies towards efgartigimod and/or rHuPH20 and the presence of neutralizing antibodies against efgartigimod and/or rHuPH20</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Time to CIDP disease progression</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
    <description>Time to CIDP disease progression is defined by the time from first dose of double-blind IMP to the first I-RODS score decrease ≥4 points compared to Stage B baseline using the centile metric.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Percentage of patients with improved functional level compared to Stage B baseline</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in adjusted INCAT score</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in MRC Sum score</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in 24-item I-RODS disability score</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in TUG score</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in mean grip strength</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Time to 10% decrease in the 24-item I-RODS</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Exposure adjusted occurrence of treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Incidence of clinically significant laboratory abnormalities</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Pre-dosing efgartigimod serum concentrations over time</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Changes of serum IgG levels over time</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Percentage of patients with and titers of binding antibodies towards efgartigimod and/or rHuPH20 and the presence of neutralizing antibodies against efgartigimod and/or rHuPH20</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</condition>
  <arm_group>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving efgartigimod PH20 SC in both stage A as stage B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>efgartigimod PH20 SC in stage B</intervention_name>
    <description>Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo in stage B</intervention_name>
    <description>Stage A: N/A, stage B: placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand the requirements of the trial, provide written informed consent
             (include consent for the use and disclosure of research-related health information),
             willingness and ability to comply with the trial protocol procedures (including
             required trial visits)

          2. Male or female patient aged 18 years or older, at the time of signing the informed
             consent.

          3. Diagnosed with probable or definite CIDP according to criteria of the European
             Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS 2010),
             progressing or relapsing forms.

          4. CIDP Disease Activity Status (CDAS) score ≥2 at screening.

          5. INCAT score ≥2, with a score of 2 exclusively from leg disability, at the first run-in
             visit (for patients entering run-in) or stage A baseline (for treatment-naïve patients
             with documented evidence for worsening on the total adjusted INCAT disability score
             within 3 months prior to screening)

          6. Fulfilling any of the following treatment conditions:

               -  Currently treated with pulsed corticosteroids, oral corticosteroids equivalent to
                  prednisolone/prednisone ≤10mg/day, and/or IVIg or SCIg, if this treatment has
                  been started within the last 5 years before screening, and the patient is willing
                  to discontinue this treatment at the first run-in visit; or

               -  Without previous treatment (treatment-naive); or

               -  Treatment with corticosteroids and/or IVIg or SCIg discontinued at least 6 months
                  prior to screening Note: Patients not treated with monthly or daily
                  corticosteroids, IVIg or SCIg for at least 6 months prior to screening are
                  considered as equal to treatment-naïve patients.

          7. Women of childbearing potential who have a negative pregnancy test at screening and a
             negative urine pregnancy test up to Stage A baseline.

          8. Women of childbearing potential must use a highly effective method of contraception
             (failure rate of less than 1% per year) from screening to 90 days after the last
             administration of IMP

          9. Non-sterilized male patients who are sexually active with a female partner of
             childbearing potential must use a condom and his partner must use a highly effective
             method of contraception (failure rate of less than 1% per year) from screening to 90
             days after the last administration of IMP. Male patients practicing true sexual
             abstinence (when this is in line with the preferred and usual life style of the
             participant) can be included. Sterilized male patients who have had vasectomy with
             documented aspermia post-procedure can be included. In addition, male patients are not
             allowed to donate sperm from screening to 90 days after the last administration of IMP

        Exclusion Criteria:

          1. Pure sensory atypical CIDP (EFNS/PNS definition).

          2. Polyneuropathy of other causes, including the following: Multifocal motor neuropathy;
             Monoclonal gammopathy of uncertain significance with anti-myelin associated,
             glycoprotein immunoglobulin M (IgM) antibodies; Hereditary demyelinating neuropathy;
             Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change
             syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to
             diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or
             toxin-induced polyneuropathy.

          3. Any other disease that could better explain the patient's signs and symptoms.

          4. Any history of myelopathy or evidence of central demyelination.

          5. Current or past history (within 12 months of screening) of alcohol, drug or medication
             abuse.

          6. Severe psychiatric disorder (such as severe depression, psychosis, bipolar disorder),
             history of suicide attempt, or current suicidal ideation that in the opinion of the
             investigator could create undue risk to the patient or could affect adherence with the
             trial protocol.

          7. Patients with clinically significant active or chronic uncontrolled bacterial, viral,
             or fungal infection at screening, including patients who test positive for an active
             viral infection at screening with: Active Hepatitis B Virus (HBV): serologic panel
             test results indicative of an active (acute or chronic) infection; Active Hepatitis C
             Virus (HCV): serology positive for HCV-Ab; Human Immunodeficiency Virus (HIV) positive
             serology associated with an Acquired Immune Deficiency Syndrome (AIDS)-defining
             condition or with a cluster of differentiation 4 (CD4) count ≤200 cells/mm3.

          8. Total IgG level &lt;6 g/L at screening.

          9. Treatment with the following: Within 3 months (or 5 half-lives of the drug, whichever
             is longer) before screening: plasma exchange or immunoadsorption, any concomitant
             Fc-containing therapeutic agents or other biological, or any other investigational
             product; Within 6 months before screening: rituximab, alemtuzumab, any other
             monoclonal antibody, cyclophosphamide, interferon, tumor necrosis factor-alpha
             inhibitors, fingolimod, methotrexate, azathioprine, mycophenolate, any other
             immunomodulating or immunosuppressive medications, and oral daily corticosteroids &gt;10
             mg/day. Note: Patients using IVIg, SCIg, pulsed corticosteroids, and oral daily
             corticosteroids ≤10 mg/day can be included.

         10. Pregnant and lactating women and those intending to become pregnant during the trial
             or within 90 days after last IMP administration.

         11. Patients with any other known autoimmune disease that, in the opinion of the
             investigator, would interfere with an accurate assessment of clinical symptoms of
             CIDP.

         12. Patients who received a live-attenuated vaccine fewer than 28 days before screening.
             Receiving an inactivated, sub-unit, polysaccharide, or conjugate vaccine any time
             before screening is not exclusionary.

         13. Patients who have a history of malignancy unless deemed cured by adequate treatment
             with no evidence of recurrence for ≥3 years before the first IMP administration.
             Patients with the following cancer can be included anytime: Adequately treated basal
             cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ
             of the breast, or Incidental histological finding of Prostate cancer (TNM [tumor,
             nodes, and metastases classification] stage T1a or T1b).

         14. Patients who previously participated in a trial with efgartigimod and have received at
             least one administration of IMP.

         15. Patients with known medical history of hypersensitivity to any of the ingredients of
             IMP.

         16. Patients with clinical evidence of other significant serious disease or patients who
             underwent a recent or have a planned major surgery, or any other reason which could
             confound the results of the trial or put the patient at undue risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Guglietta, MD</last_name>
    <phone>+1 857-350-4834</phone>
    <email>ClinicalTrials@argenx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site 6</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 10</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 9</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 8</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <zip>11772</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 11</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 16</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 13</name>
      <address>
        <city>Białystok</city>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 15</name>
      <address>
        <city>Katowice</city>
        <zip>40-650</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 17</name>
      <address>
        <city>Kraków</city>
        <zip>30-539</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 12</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 14</name>
      <address>
        <city>Łódź</city>
        <zip>90-324</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

